News

BDR Pharma partners with Varenyam Healthcare

To revolutionise anaesthesia practices in India

BDR Pharmaceuticals and Varenyam Healthcare announced the launch of Sugmadex – an innovation, bringing to India a first of its kind drug in over 10 years with novel γ-cyclodextrin neuromuscular block (NMB) reversal properties. Sugmadex (Sugammadex 100mg/ml) is a pioneer in Anaesthesia drugs offering safe, rapid and complete reversal of shallow, moderate and deep neuromuscular block (NMB), resulting in the removal of anaesthesia effect on the body.

Currently, available reversal agents cannot reverse profound NMB & quite often result in postoperative respiratory complications. The clinical use of Sugmadex is a breakthrough that promises to eliminate many of the shortcomings in current anaesthetic practice. Sugmadex is available as 2 ml & 5 ml single-dose vials.

Commenting on the launch, Raheel Shah, Director Business Development on behalf of BDR Pharmaceuticals Int’l, Mumbai said, “The results collated from the Indian trials on patients promise to be advantageous for the users lacking any side effects. Sugmadex is set to be the game-changer in the segment of reversal agents in modern-day surgery. This product is testament to our objective of bringing innovation with the introduction of Novel drugs which were not present in the domestic market previously.”

This first of its kind new generation drug in India, Sugmadex is going to be more efficient, effective and life-saving for patients with severe complications thereby improving the overall rate of recovery.

Bhahim Desai, CEO, Varenyam Healthcare commented, “Varenyam has a standing commitment with the Anaesthesia fraternity to bring Ambulatory Anaesthesia practices to India. This alliance shows our commitment to bringing innovation and excellence to safe and novel anaesthesia practices in India. Varenyam’s trained and experienced sales team, specialised in promotion and ethical sales of anaesthesia products, will enable penetrating the deep end of the market.”

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Back to top button
Close
Close